Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Gemtesa is approved for men with overactive bladder symptoms who are receiving pharmacologic treatment for benign prostatic hyperplasia.

An overactive bladder may be temporary or become a chronic condition. How long the symptoms last may depend on factors like the underlying cause and treatment adherence. Some conditions may cause ...

While drinking adequate water remains essential for health, timing fluid intake can help manage symptoms. Reducing evening fluid consumption often improves nighttime bladder control. Some individuals ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

CHRISTMAS can be a hectic time, with the pressure to buy gifts, cook large meals, and travel to see family. But like any time ...

It's a CR Best Buy because it has a lower risk of side effects. You might not even have an overactive bladder. Symptoms that are associated with diabetes, kidney stones, multiple sclerosis ...

This sham was used in the placebo arm of the Study of Urgent PC vs Sham Effectiveness in Treatment of Overactive Bladder Symptoms (SUmiT) trial. This was a multicenter, placebo controlled ...

The term "voiding dysfunction" has been used to refer to urinary incontinence, urinary retention and symptoms of frequency and urgency. Overactive bladder is a specific type of voiding dysfunction ...

An increase in overactive bladder (OAB) diagnoses was seen following publication of the first OAB guideline, and the rate of third-line therapy procedures also increased, according to a study ...